Previous 10 | Next 10 |
Gainers: Cocrystal Pharma (COCP) +97%, BioLineRx (BLRX) +51%, Neuronetics (STIM) +21%, Shineco (TYHT) +20%, Precipio (PRPO) +14%.Losers: ChemoCentryx (CCXI) -38%, Regional Health Properties (RHE) -35%, Brooklyn ImmunoTherapeutics (BTX) -3...
Image source: The Motley Fool. ChemoCentryx Inc (NASDAQ: CCXI) Q1 2021 Earnings Call Apr 30, 2021 , 9:00 p.m. ET Operator Continue reading For further details see: ChemoCentryx Inc (CCXI) Q1 2021 Earnings Call Transcript
ChemoCentryx, Inc. (CCXI) Q1 2021 Earnings Conference Call April 29, 2021, 5:00 PM ET Company Participants Lee Roth - Burns McClellan, IR Dr. Thomas Schall - President and CEO Susan Kanaya - Executive Vice President, Chief Financial and Administrative Officer Tosh Butt - Chief Operating Offic...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: ChemoCentryx, Inc. 2021 Q1 - Results - Earnings Call Presentation
ChemoCentryx (CCXI): Q1 GAAP EPS of -$0.43 misses by $0.03.Revenue of $10.35M (+72.2% Y/Y) beats by $2.42M.Press Release For further details see: ChemoCentryx EPS misses by $0.03, beats on revenue
-- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July 7, 2021, with Advisory Committee scheduled for May 6 -- -- Novel orally administered checkpoint inhibitor CCX559 feature...
MOUNTAIN VIEW, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2021 financial results will be released after market close on Thursday, April 29, 2021. ChemoCentryx executive management will host a conference cal...
-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- -- Company plans to advance CCX559 into clinical development in the first half of 2021 -- MOUNTAIN VIEW, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- ChemoCen...
MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET. The event will feature a panel of key opinion leaders, a testimonial from a patient ...
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective Ma...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...